Thrombophilia in Pregnancy

AuthorCristina Hotoleanuen
Issued Date2019-01-31en
AbstractPregnancy represents a physiologic hypercoagulable state. The presence of inherited thrombophilias (factor V Leiden, prothrombin G20210A mutation, deficiencies of protein C, protein S and antithrombin) or acquired thrombophilias (antiphospholipid syndrome) increases the risk for venous thromboembolism, which represents one of the most common causes of direct maternal death. The clinical diagnosis of thrombosis can be difficult because of the overlap of symptoms with pregnancy-related manifestations. Antiphospholipid syndrome is correlated with early and late pregnancy complications whereas the association between the inherited thrombophilias and adverse pregnancy outcomes is still controversial. The psychological impact of thrombophilia in pregnancy should be also taken into consideration to prevent the negative effects of anxiety and stress on mother’s health and on birth outcomes. Thrombophilia testing in pregnancy is recommended only in cases in which the result is likely to influence the therapeutic decision. Low-molecular-weight heparins are the preferred anticoagulant for prophylaxis and therapy of thromboembolic events in pregnancy, presenting a low incidence of side effects. Future research is required to establish the optimal therapeutic strategy in pregnant women with thrombophilia, based upon a better stratification, in order to prevent thromboembolism and to improve pregnancy outcomes.en
DOIhttps://doi.org/10.21859/ijcp-404en
URIhttps://brieflands.com/journals/ijcp/articles/130278en
KeywordVenous Thrombosisen
KeywordVenous Thromboembolismen
KeywordThrombophiliaen
KeywordPregnancyen
PublisherBrieflandsen
TitleThrombophilia in Pregnancyen
TypeReview Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
16845.pdf
Size:
570.06 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF